Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression

Authors: Tomasz Banas, Kazimierz Pitynski, Krzysztof Okon, Aleksandra Winiarska

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The expression of DNA fragmentation factor 45 (DFF45) and B-cell lymphoma 2 (BCL2) in glands of the normal human endometrium is related to phases of the menstrual cycle and decreases after menopause, whereas the expression of DNA fragmentation factor 40 (DFF40) is stable. Moreover, DF45, BCL2 and DFF40 underexpression has been reported in numerous malignancies, including uterine leiomyosarcomas. In this study, we aimed to investigate DFF45, BCL2 and DFF40 expression in endometrioid and non-endometrioid types of endometrial cancers (ECs). We also evaluated the correlations between DFF45, BCL2 and DFF40 expression levels and clinicopathological parameters and determined the value of these three proteins as prognostic markers of disease-free survival (DFS) and overall survival (OS).

Methods

Immunohistochemistry was performed to evaluate DFF45, BCL2 and DFF40 expression in 342 cases of ECs. Student’s t-test, the Mann-Whitney U-test, and the chi-squared test were used for the statistical analyses as appropriate. The Cox-Mantel test, Cox’s proportional hazard model, and relative risk analyses were used to evaluate associations between DFF40, DFF45, and BCL2 expression and clinicopathological characteristics.

Results

DFF40 and BCL2, but not DFF45, were significantly underexpressed in non-endometrioid and high-grade endometrioid ECs compared with low- and moderate-grade endometrioid ECs. Women with DFF40- and BCL2-negative tumors had higher risks of disease recurrence, lymph node involvement, lympho-vascular space infiltration, and deep myometrial invasion compared with women with DFF40- and BCL2-positive tumors. Additionally, women with DFF40- and BCL2-negative tumors had significantly lower OS and DFS than women with DFF40- and BCL2-positive tumors. A multivariable analysis of the model, including the clinicopathological characteristics and immunohistochemical results, showed that negative BCL2 expression, lymph node involvement, and high-stage and high-grade disease were independent predictors of OS, whereas negative BCL2 expression, lymph node involvement, and high-stage disease were independent predictors of DFS.

Conclusions

Compared with low- and moderate-grade endometrioid ECs, non-endometrioid and high-grade endometrioid ECs showed significant DFF40 and BCL2 underexpression. The absence of DFF40 and BCL2 expression negatively affects DFS and OS. Further prospective studies are warranted to assess the potential utility of DFF40 and BCL2 as targets in the diagnosis or treatment of ECs.
Literature
1.
Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207–25.CrossRefPubMed
2.
Banas T, Juszczyk G, Pitynski K, Nieweglowska D, Ludwin A, Czerw A. Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980-2013): an analysis of population-based data in relation to socioeconomic changes. Onco Targets Ther. 2016;9:5521–30.CrossRefPubMedPubMedCentral
3.
4.
5.
Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol. 2016;29(Suppl 1):S29–44.CrossRefPubMed
6.
Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol. 2003;22:324–33.CrossRefPubMed
7.
Kihara A, Yoshida H, Watanabe R, Takahashi K, Kato T, Ino Y, Kitagawa M, Hiraoka N. Clinicopathologic association and prognostic value of microcystic, elongated, and fragmented (MELF) pattern in endometrial Endometrioid carcinoma. Am J Surg Pathol. 2017;41:896–905.CrossRefPubMed
8.
Hertel JD, Huettner PC, Pfeifer JD. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol. 2014;33:127–34.CrossRefPubMed
9.
Dogan Altunpulluk M, Kir G, Topal CS, Cetiner H, Gocmen A. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis. J Obstet Gynaecol. 2015;35:397–402.CrossRefPubMed
10.
Joehlin-Price AS, McHugh KE, Stephens JA, Li Z, Backes FJ, Cohn DE, Cohen DW, Suarez AA. The microcystic, elongated, and fragmented (MELF) pattern of invasion: a single institution report of 464 consecutive FIGO grade 1 endometrial Endometrioid adenocarcinomas. Am J Surg Pathol. 2017;41:49–55.CrossRefPubMedPubMedCentral
11.
Zinovkin DA, Pranjol MZI, Petrenyov DR, Nadyrov EA, Savchenko OG. The potential roles of MELF-pattern, microvessel density, and VEGF expression in survival of patients with Endometrioid endometrial carcinoma: a Morphometrical and Immunohistochemical analysis of 100 cases. J Pathol Transl Med. 2017;51:456–62.CrossRefPubMedPubMedCentral
12.
Thoury A, Descatoire V, Kotelevets L, Kannengiesser C, Bertrand G, Theou-Anton N, Frey C, Genestie C, Raymond E, Chastre E, Lehy T, Walker F. Evidence for different expression profiles for c-met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability. Histol Histopathol. 2014;29:1455–66.PubMed
13.
Pitynski K, Banas T, Pietrus M, Milian-Ciesielska K, Ludwin A, Okon K. SOX-2, but not Oct4, is highly expressed in early-stage endometrial adenocarcinoma and is related to tumour grading. Int J Clin Exp Pathol. 2015;8:8189–98.PubMedPubMedCentral
14.
Pitynski K, Ozimiek T, Gałuszka N, Banas T, Milian-Ciesielska K, Pietrus M, Okon K, Mikos M, Juszczyk G, Sinczak-Kuta A, Sloj A. Association of the immunohistochemical detection of gamma-glutamyl transferase expression with clinicopathological findings in postmenopausal women with endometrioid adenocarcinoma of the uterus. J Physiol Pharmacol. 2016;67:295–402.
15.
Yu CG, Jiang XY, Li B, Gan L, Huang JF. Expression of ER, PR, C-erbB-2 and Ki-67 in endometrial carcinoma and their relationships with the Clinicopathological features. Asian Pac J Cancer Prev. 2015;16:6789–94.CrossRefPubMed
16.
Brustmann H. Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues. Pathol Res Pract. 2007;203:65–72.CrossRefPubMed
17.
Fukushima K, Kikuchi J, Koshiba S, Kigawa T, Kuroda Y, Yokoyama S. Solution structure of the DFF-C domain of DFF45/ICAD. A structural basis for the regulation of apoptotic DNA fragmentation. J Mol Biol. 2002;321:317–27.CrossRefPubMed
18.
Toh SY, Wang X, Li P. Identification of the nuclear factor HMG2 as an activator for DFF nuclease activity. Biochem Biophys Res Commun. 1998;250:598–601.CrossRefPubMed
19.
Banas T, Pitynski K, Mikos M, Cielecka-Kuszyk J. Endometrial polyps and benign endometrial hyperplasia present increased prevalence of DNA fragmentation factors 40 and 45 (DFF40 and DFF45) together with the Antiapoptotic B-cell lymphoma (Bcl-2) protein compared with normal human endometria. Int J Gynecol Pathol. 2017; https://​doi.​org/​10.​1097/​PGP.​0000000000000442​. [Epub ahead of print]
20.
Banas T, Pitynski K, Okon K, Czerw A. DNA fragmentation factors 40 and 45 (DFF40/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival. Onco Targets Ther. 2017;10:4579–89.CrossRefPubMedPubMedCentral
21.
McGurgan P, Taylor LJ, Duffy SR, O’Donovan PJ. An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to HRT. Maturitas. 2006;53:454–61.CrossRefPubMed
22.
Minn AJ, Valez P, Schendel SL, Liang M, Muchmore SW, Fesik SW, Fill M, Thompson CB. Bcl-x(L) forms an ion channel in synthetic lipid membramnes. Nature. 1997;385:353–7.CrossRefPubMed
23.
Erdem O, Erdem M, Dursum A, Akyol G, Erdem A. Angiogenesis, p53, and BCL2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathological variables. Int J Gynecol Pathol. 2003;22:254–60.CrossRefPubMed
24.
SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F. Society of Gynecologic Oncology Clinical Practice Committee.. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134:385–92.CrossRef
25.
Yigit S, Demir L, Tarhan MO, Cabuk FK, Ellidokuz H, Erten C, Somali I, Dirican A, Cakalagaoglu F. The clinicopathological significance of Bax and BCL2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. Neoplasma. 2012;59:475–85.CrossRefPubMed
26.
Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, Roberts C, Shoukri M, Streiner DL. Guidelines for reporting reliability and agreement studies (GRRAS) were proposed. Int J Nurs Stud. 2011;48:661–71.CrossRefPubMed
27.
Suarez AA, Felix AS, Cohn DE. Bokhman redux: endometrial cancer “types” in the 21st century. Gynecol Oncol. 2017;144:243–9.CrossRefPubMed
28.
Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, Gass ML, Kuller LH, Pfeiffer RM, Rohan TE, Strickler HD, Xu X, Wentzensen N. Serum estrogens and estrogen metabolites and endometrial Cancer risk among postmenopausal women. Cancer Epidemiol Biomark Prev. 2016l;25:1081–9.CrossRef
29.
Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, Hollenbeck A, Park Y, Sherman ME, Brinton LA. Endometrial cancer risk factors by 2 main histologic subtypes. The NIH-AARP diet and health study. Am J Epidemiol. 2013;177:142–51.CrossRefPubMed
30.
Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol. 1997;10:963–8.PubMed
31.
Sakuragi N, Salah-eldin AE, Watari H, Itoh T, Inoue S, Moriuchi T, Fujimoto S. Bax, BCL2, and p53 expression in endometrial cancer. Gynecol Oncol. 2002;86:288–96.CrossRefPubMed
32.
Morsi HM, Leers MP, Radespiel-Tröger M, Björklund V, Kabarity HE, Nap M, Jäger W. Apoptosis, BCL2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry. Gynecol Oncol. 2000;77:11–7.CrossRefPubMed
33.
Loffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (BCL2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol. 1998;29:1150–9.CrossRef
34.
Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, Margaritis L, Panotopoulou E. BCL2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry. Anticancer Res. 2009;29:3977–82.PubMed
35.
Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. Lack of BCL2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol. 1998;71:305–7.CrossRefPubMed
36.
Brustmann H. Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. Int J Gynecol Pathol. 2013;32:384–9.CrossRefPubMed
37.
Errami Y, Brim H, Oumouna-Benachour K, Oumouna M, Naura AS, Kim H, Ju J, Davis CJ, Kim JG, Ashktorab H, Fallon K, Xu M, Zhang J, Del Valle L, Boulares AH. ICAD deficiency in human colon cancer and predisposition to colon tumorigenesis: linkage to apoptosis resistance and genomic instability. PLoS One. 2013;8:e57871.CrossRefPubMedPubMedCentral
38.
Konishi S, Ishiguro H, Shibata Y, Kudo J, Terashita Y, Sugiura H, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y, Fujii Y. Decreased expression of DFF45/ICAD is correlated with a poor prognosis in patients with esophageal carcinoma. Cancer. 2002;95:2473–8.CrossRefPubMed
39.
Judson H, van Roy N, Strain L, Vandesompele J, Van Gele M, Speleman F, Bonthron DT. Structure and mutation analysis of the gene encoding DNA fragmentation factor 40 (caspase-activated nuclease), a candidate neuroblastoma tumour suppressor gene. Hum Genet. 2000;106:406–13.CrossRefPubMed
40.
George J, Banik NL, Ray SK. BCL2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. 2009;34:66–78.CrossRefPubMed
41.
Yamaguchi K, Uzzo R, Dulin N, Finke JH, Kolenko V. Renal carcinoma cells undergo apoptosis without oligonucleosomal DNA fragmentation. Biochem Biophys Res Commun. 2004;318:710–3.CrossRefPubMed
42.
Mizuta R, Mizuta M, Araki S, Suzuki K, Ebara S, Furukawa Y, Shiokawa D, Tanuma S, Kitamura D. DNase gamma-dependent and -independent apoptotic DNA fragmentations in Ramos Burkitt's lymphoma cell line. Biomed Res. 2009;30:165–70.CrossRefPubMed
43.
Luciano F, Ricci JE, Herrant M, Bertolotto C, Mari B, Cousin JL, Auberger P. T and B leukemic cell lines exhibit different requirements for cell death: correlation between caspase activation, DFF40/DFF45 expression, DNA fragmentation and apoptosis in T cell lines but not in Burkitt’s lymphoma. Leukemia. 2002;16:700–7.CrossRefPubMed
44.
Bagheri F, Safarian S, Eslaminejad MB, Sheibani N. Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide. Mol Biol Rep. 2014;41:7387–94.CrossRefPubMedPubMedCentral
45.
Bagheri F, Safarian S, Eslaminejad MB, Sheibani N. Sensitization of breast cancer cells to doxorubicin via stable cell line generation and overexpression of DFF40. Biochem Cell Biol. 2015;93:604–10.CrossRefPubMedPubMedCentral
46.
Banas T, Skotniczny K, Basta A. DFF45 expression in ovarian endometriomas. EJOGRB. 2009;146:87–91.
47.
Widlak P, Garrard WT. Roles of the major apoptotic nuclease-DNA fragmentation factor-in biology and disease. Cell Mol Life Sci. 2009;66:263–74.CrossRefPubMed
48.
Grevenkamp F, Kommoss F, Kommoss F, Lax S, Fend F, Wallwiener D, Schönfisch B, Krämer B, Brucker SY, Taran FA, Staebler A, Kommoss S. Second opinion expert pathology in endometrial Cancer: potential clinical implications. Int J Gynecol Cancer. 2017;27:289–96.CrossRefPubMed
Metadata
Title
Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression
Authors
Tomasz Banas
Kazimierz Pitynski
Krzysztof Okon
Aleksandra Winiarska
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4333-6

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Study protocol

A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHOICE): study protocol

Research article

NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia

Research article

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus

Case report

Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma

Research article

Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?

Research article

Dynamic imaging and pathological changes in pig liver after MR-guided microwave ablation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits